Skip to main content

Hybrigenics Acquires Dutch Oncology Target Company Semaia

NEW YORK, April 29 - Hybrigenics has acquired Dutch oncology target discovery company Semania, the companies said today.

 

The acquisition, in which Hybrigenics purchased 100 percent of Semaia's shares, enables Hybrigenics access to Semaia's oncology targets. These include therapeutic targets, both enzymes and cell surface proteins, in the Wnt pathway of colorectal cancer, and in the Ras-Raf and PKB/AKT pathways in other cancers.

 

Hybrigenics, of Paris, will use its yeast-two hybrid proteomics technology to explore the function of Semaia's targets and identify proteins that interact with these targets, the company said.

The company also said it expects the acquisition to "reinforce the international collaborations" it has with research institutes. Semaia, of Utrecht, was co-founded by Professors Hans Bos and Hans Clevers of the University of Utrecht. 

 

In the acquisition, Semiaia CEO Rian De Jonge will become Hybrigenics' executive vice president of R&D, and Bos and Clevers will join Hybrigenics' scientific advisory board.

 

Hybrigenics currently has drug discovery programs in cancer and in infectious diseases including HIV and Hepatitis C.

 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.